← Back to patent-cliff list
CAS 121584-52-9
Cyclo[[3(R)-acetoxy-N2,4(R)-dimethyl-6-oxo-L-norleucyl]-L-2-aminobutyryl-N-methyl-G-N-methyl-LV-N-methyl-LAa-N-methyl-L-N-methyl-L-N-methyl-V]
Codes: Voclosporin-004
Application context (from source-drug indications)
狼疮肾炎VoclosporinKidney transplant rejectionVoclosporinCOVID-19VoclosporinSystemic lupus erythematosusVoclosporin局灶性节段性肾小球硬化症VoclosporinDry eye syndromeVoclosporin
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Voclosporin | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
Cyclo{-[4-( E)-but-2-enyl- N,4-dimethyl- L-threonyl]-L-homoalanyl-(N-methylglycyl)-( N-methyl-L-leucyl)-L-valyl-( N-me-thyl- L-leucyl)-L-alanyl- D-alanyl-(N-methyl-L-leucyl)-( N-methyl-L-leucyl)-(N-methyl-L-valyl)-}→(1R,2R,4E)-1-[(2S,5S,11S,14S,17S,20S,23R,26S,29S,32S)-5-Ethyl-1,7,10,16,20,23,25,28,31-nonamethyl-11,17,26,29-tetrakis(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-14,32-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2-yl]-2-methylhex-4-en-1-ylacetate→(1R,2R,4E)-1-[(2S,5S,11S,14S,17S,20S,23R,26S,29S,32S)-5-Ethyl-1,7,10,16,20,23,25,28,31-nonamethyl-11,17,26,29-tetrakis(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-14,32-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2-yl]-2-methylhex-4-en-1-ylbenzoate→Cyclo[[3(R)-acetoxy-N2,4(R)-dimethyl-6-oxo-L-norleucyl]-L-2-aminobutyryl-N-methyl-G-N-methyl-LV-N-methyl-LAa-N-methyl-L-N-methyl-L-N-methyl-V]→(1R,2R)-1-[(2S,5S,11S,14S,17S,20S,23R,26S,29S,32S)-5-Ethyl-1,7,10,16,20,23,25,28,31-nonamethyl-11,17,26,29-tetrakis(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-14,32-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2-yl]-2-methyl-4-oxobutylbenzoate
Cyclo[[3(R)-acetoxy-N2,4(R)-dimethyl-6-oxo-L-norleucyl]-L-2-aminobutyryl-N-methyl-G-N-methyl-LV-N-methyl-LAa-N-methyl-L-N-methyl-L-N-methyl-V]→(1R,2R)-1-[(2S,5S,11S,14S,17S,20S,23R,26S,29S,32S)-5-Ethyl-1,7,10,16,20,23,25,28,31-nonamethyl-11,17,26,29-tetrakis(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-14,32-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2-yl]-2-methyl-4-oxobutylbenzoate→Triphenyl(prop-2-en-1-yl)phosphoniumbromide→(1R,2R,4E)-1-[(2S,5S,11S,14S,17S,20S,23R,26S,29S,32S)-5-Ethyl-1,7,10,16,20,23,25,28,31-nonamethyl-11,17,26,29-tetrakis(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-14,32-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2-yl]-2-methylhepta-4,6-dien-1-ylacetate→(1R,2R,4E)-1-[(2S,5S,11S,14S,17S,20S,23R,26S,29S,32S)-5-Ethyl-1,7,10,16,20,23,25,28,31-nonamethyl-11,17,26,29-tetrakis(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-14,32-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2-yl]-2-methylhepta-4,6-dien-1-ylbenzoate→[Phenyl(prop-2-en-1-yl)phosphoroso]benzene→Dimethylallylphosphonate
Cyclo[[3(R)-acetoxy-N2,4(R)-dimethyl-6-oxo-L-norleucyl]-L-2-aminobutyryl-N-methyl-G-N-methyl-LV-N-methyl-LAa-N-methyl-L-N-methyl-L-N-methyl-V]→trimethyl[(1E)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-1-en-1-yl]silane→(1R,2R,4R,5R)-1-[(2S,5S,11S,14S,17S,20S,23R,26S,29S,32S)-5-ethyl-14,32-diisopropyl-1,7,10,16,20,23,25,28,31-nonamethyl-11,17,26,29-tetrakis(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2-yl]-4-hydroxy-2-methyl-5-(trimethylsilyl)hept-6-en-1-ylacetate
Cyclo{-[4-( E)-but-2-enyl- N,4-dimethyl- L-threonyl]-L-homoalanyl-(N-methylglycyl)-( N-methyl-L-leucyl)-L-valyl-( N-me-thyl- L-leucyl)-L-alanyl- D-alanyl-(N-methyl-L-leucyl)-( N-methyl-L-leucyl)-(N-methyl-L-valyl)-}→(1R,2R,4E)-1-[(2S,5S,11S,14S,17S,20S,23R,26S,29S,32S)-5-Ethyl-1,7,10,16,20,23,25,28,31-nonamethyl-11,17,26,29-tetrakis(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-14,32-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2-yl]-2-methylhex-4-en-1-ylacetate→Cyclo[[3(R)-acetoxy-N2,4(R)-dimethyl-6-oxo-L-norleucyl]-L-2-aminobutyryl-N-methyl-G-N-methyl-LV-N-methyl-LAa-N-methyl-L-N-methyl-L-N-methyl-V]
Cyclo[[3(R)-acetoxy-N2,4(R)-dimethyl-6-oxo-L-norleucyl]-L-2-aminobutyryl-N-methyl-G-N-methyl-LV-N-methyl-LAa-N-methyl-L-N-methyl-L-N-methyl-V]→3-(Trimethylsilyl)propyne→(1R,2R,4E)-1-[(2S,5S,11S,14S,17S,20S,23R,26S,29S,32S)-5-Ethyl-1,7,10,16,20,23,25,28,31-nonamethyl-11,17,26,29-tetrakis(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-14,32-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2-yl]-2-methylhepta-4,6-dien-1-ylacetate
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.